18,031 Shares in Geron Co. (NASDAQ:GERN) Bought by Crestline Management LP

Crestline Management LP acquired a new position in shares of Geron Co. (NASDAQ:GERN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 18,031 shares of the biopharmaceutical company’s stock, valued at approximately $64,000.

Several other large investors have also modified their holdings of the company. Rovin Capital UT ADV boosted its holdings in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares during the period. Xponance Inc. boosted its holdings in shares of Geron by 12.9% during the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,829 shares during the period. KBC Group NV boosted its holdings in shares of Geron by 45.1% during the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 7,592 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of Geron during the 4th quarter worth $28,000. Finally, Lazari Capital Management Inc. boosted its holdings in shares of Geron by 11.7% during the 4th quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company’s stock worth $271,000 after buying an additional 8,000 shares during the period. 73.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on GERN. Scotiabank downgraded shares of Geron from a “sector outperform” rating to a “sector perform” rating and reduced their price target for the company from $4.00 to $1.50 in a report on Thursday. HC Wainwright reissued a “neutral” rating on shares of Geron in a report on Wednesday, March 12th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and reduced their price target for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Stifel Nicolaus reduced their price target on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.06.

Geron Price Performance

NASDAQ:GERN opened at $1.19 on Monday. The company has a 50-day moving average of $1.49 and a 200-day moving average of $2.72. The company has a market capitalization of $754.75 million, a price-to-earnings ratio of -3.70 and a beta of 0.76. Geron Co. has a 52 week low of $1.17 and a 52 week high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $39.60 million during the quarter, compared to the consensus estimate of $49.88 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm’s revenue for the quarter was up 12927.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.07) EPS. As a group, equities research analysts anticipate that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.